MONTREAL, April 6 /CNW/ - Aptilon Corporation (the "Corporation") (TSX
Venture Exchange: APZ), a leader in providing pharmaceutical companies with
online sales channels to physicians, today announced that the Corporation's
directors adopted a resolution on April 3, 2009 to reduce the exercise price
of its 12,818,100 issued and outstanding options to purchase Class A Shares of
the Corporation. The reduced exercise price will be $0.105 per share, being
the closing price of the Class A Shares of the Corporation on April 2, 2009.
The reduction of the exercise price is subject to the approval of the TSX
Venture Exchange (the "Exchange") in the case of the 2,162,500 options held by
non-insiders of the Corporation.
In the case of the 10,655,600 options held by insiders of the
Corporation, the reduction is subject to the approval of the Exchange and to
the approval of disinterested shareholders (as defined in the applicable
Exchange policy) at the next annual meeting of shareholders to be held in June
2009.
The following table summarizes the terms and conditions of the options
held by insiders:-------------------------------------------------------------
Grant date 13-Sep-05 8-Dec-06 12-Dec-06 23-Jan-07 21-Dec-07 Total
-------------------------------------------------------------------------
André Charron 50,000 50,000 0 100,000
-------------------------------------------------------------------------
Antoine Goulet 100,000 0 100,000
-------------------------------------------------------------------------
Denis Martineau 900,000 900,000 0 1,800,000
-------------------------------------------------------------------------
Frank Lin 100,000 150,000 250,000
-------------------------------------------------------------------------
Mark Benthin 900,000 900,000 0 1,800,000
-------------------------------------------------------------------------
Mark Gleason 1,000,000 100,000 1,100,000
-------------------------------------------------------------------------
André
Brosseau 100,000 3,400,000 0 3,500,000
-------------------------------------------------------------------------
Tommy Boman 105,600 50,000 50,000 0 205,600
-------------------------------------------------------------------------
Roger Korman 900,000 900,000 0 1,800,000
-------------------------------------------------------------------------
Original
Exercise
Price $ 0.200 $ 0.200 $ 0.200 $ 0.255 $ 0.250 10,655,600
--------------------------------------------------------------
Expiry
date 13-Sep-10 8-Dec-11 12-Dec-11 23-Jan-12 21-Dec-12 Total
--------------------------------------------------------------
All the options are subject to the Corporation's stock option plan.
About Aptilon Corporation
-------------------------Aptilon enables pharmaceutical, biotech and medical device companies to
effectively reach and interact with more than 450,000 US physicians via the
Internet through its innovative AxcelRx(SM) Live video detailing platform
which hosts promotional, peer selling and other sales and marketing programs.
Top ten US pharmaceutical companies have adopted Aptilon's AxcelRx(SM)
solution to reach leading physicians. Aptilon provides the infrastructure
necessary for pharmaceutical companies to build physician awareness,
understanding, and product preference during all stages of a product's life
cycle, from pre-launch education through end stage support. For more
information, visit www.aptilon.com.
AxcelRx(SM) and ReachNet(SM) are service marks of Aptilon Corporation.Forward-looking statements
--------------------------This news release may contain forward-looking information. These
statements relate to future events or future performance and reflect
management's current expectations and assumptions. Such forward-looking
statements reflect management's current beliefs and are based on information
currently available to management of Aptilon. A number of factors could cause
actual events, performance or results to differ materially from the events
performance and results discussed in the forward-looking statements. These
forward-looking statements are made as of the date hereof and Aptilon does not
assume any obligation to update or revise them to reflect new events or
circumstances.The TSX Venture Exchange does not assume any liability regarding the
relevancy or the accuracy of this news release.%SEDAR: 00022191EF
For further information: Mr. Denis Martineau, President, Aptilon
Corporation, (514) 844-8866, dmartineau@aptilon.com
